I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Ophthalmology ASRS 2024
Roche and Genentech at

ASRS 2024

July 17 - July 20
Stockholm, Sweden
asrs.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
06:00 AM
Duration 8mins Stockholm, Sweden
Assessing the Strength of Clinical Practice Guidelines for Managing Diabetic Macular Edema- a Systematic Literature Review
McAllister M, Ko S, Tabano D, Bawa K, Mearns E, Faux N, Patel S, Spicer G, Martinez A, Lim J
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8mins Stockholm, Sweden
Assessing the Strength of Clinical Practice Guidelines for Managing Neovascular Age-related Macular Degeneration- a Systematic Literature Review
Faux N, Ko S, Tabano D, Bawa K, Mearns E, McAllister M, Patel S, Spicer G, Martinez A, Lim J
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8mins Stockholm, Sweden
Assessment of the Clinical Effects of Anti-Ang-2 With Faricimab▼ Based on Key Outcomes from the YOSEMITE/RHINE Trials in Patients with DME
Kim J, Manoharan N, Amador M, Willis J, Souverain A, Stoilov I, Mar F, Gibson K
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8mins Stockholm, Sweden
Key Clinical and Anatomical Outcomes With Faricimab▼ in Patients With nAMD: Results From the TENAYA/LUCERNE Trials
Avery R, Amador M, Kotecha A, Margaron P, Stoilov I, Yang M
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8mins Stockholm, Sweden
Extended Interval Treatment Outcomes and the Potential for Q20W Dosing for the Treatment of Neovascular Age-Related Macular Degeneration With Faricimab▼: a Post Hoc Analysis of the TENAYA/LUCERNE Trials
Patel P, Ambresin A, Koh A, Singer M, Hill L, Kotecha A, Margaron P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8mins Stockholm, Sweden
Extended Treatment Outcomes and the Potential for Q20W Dosing With Faricimab▼ in Patients With DME: A Post Hoc Analysis of YOSEMITE/RHINE
Modi Y, Adam M, Gibson K, Sim D, Amador M, Hill L, Singer M
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 8mins Stockholm, Sweden
Predictors of Outcomes at Year 1 in Patients Treated With Faricimab▼ in TENAYA/LUCERNE
Dhoot D, Kim J, Stoilov I, Yang M, Hill L
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:35 AM
Duration 3mins Stockholm, Sweden
Efficacy and Safety of Faricimab▼ in ALTIMETER: A Trial Exploring Biomarkers of Ang-2 Inhibition in Patients With DME
Jhaveri C, Dang S, Amador M, Dieckmann A, Gibson K, Glittenberg C, Kotak A, Mar F, Souverain A, Titz B, Vujosevic S, Fawzi A
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 3mins Stockholm, Sweden
Greater reduction in hard exudates with faricimab▼ vs aflibercept in patients with DME: biomarker results from the phase 3 YOSEMITE/RHINE trials
Ip M, Goldberg R, Amador M, Dinah C, Gibson K, Glittenberg C, Maunz A, O'Leary O, Rahimy E, Uschner D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 3mins Stockholm, Sweden
Four-Year Outcomes of Faricimab▼ in DME: First Time Safety and Efficacy Results From the RHONE-X Long-Term Extension Trial
Khanani A, Kotecha A, Harrell E, Abreu F, Tang Y, Willis J, Sim D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:40 AM
Duration 4mins Stockholm, Sweden
12-Month Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With Diabetic Macular Edema: The FARETINA-DME Study
Leng T, Borkar D, Tabano D, Ko S, Shaia J, Myers R, Ali F, Singh R
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:15 AM
Duration 4mins Stockholm, Sweden
Efficacy, Safety, and Durability of Faricimab▼ in Macular Edema Due to Retinal Vein Occlusion: 72-week Results From the Phase 3 BALATON and COMINO Trials
Danzig C, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris L, Retiere A, Willis J
Ophthalmology | Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 1hr Stockholm, Sweden
Changing the DME Gameplan with Faricimab▼
Arshad Khanani, Veeral Sheth, Patricia Udaondo, Raj Mukherjee
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
11:00 AM
Duration 3mins Stockholm, Sweden
Clinical Benefits of Continuous Delivery of Anti-VEGF Ranibizumab with the Port Delivery System in Neovascular Age-Related Macular Degeneration
Rachitskaya A, Holekamp N, Dauletbekov D, Blotner S, Heinrich D
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 3mins Stockholm, Sweden
Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: First Readout of 2-Year Data From the Phase 3 Pavilion Trial
Chang M, Khanani A, Holmes W, Latkany P, Menezes A, Santhanakrishnan A, Wetzel-Smith M
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 3mins Stockholm, Sweden
Port Delivery System With Ranibizumab for Continuous Treatment of Diabetic Macular Edema: First Readout of the Phase 3 Pagoda Trial Year 2 Results
Awh C, Bobbala A, Howard D, Gune S, Malhotra V, Quezada-Ruiz C, Rabena M
Ophthalmology | Diabetic Retinopathy

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 3mins Stockholm, Sweden
Technical Updates to Port Delivery System With Ranibizumab (PDS) and Clinical Experience With Updated Refill Needle
Pieramici D, Pearce I, Campochiaro P, Chang M, Holekamp N, Gune S, Quezada Ruiz C, Singh N, Wise G, Ranade S, Horvath J, Regillo C
Ophthalmology | Diabetic Macular Edema

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
06:42 AM
Duration 4mins Stockholm, Sweden
Pigment Epithelial Detachment Outcomes With Faricimab▼ vs Aflibercept in Patients With nAMD: Results From TENAYA/LUCERNE
Ambresin A, Khanani A, Lai T, Lim J, London N, Kotecha A, Margaron P, Patel S, Souverain A, Willis J, Yang M
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
09:30 AM
Duration 1hr Stockholm, Sweden
Changing the nAMD Gameplan with Faricimab▼
SriniVas Sadda, Aude Ambresin, Boris Stanzel, Praveen Patel
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
12:32 PM
Duration 6mins Stockholm, Sweden
IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials
Loewenstein A, Suhler E, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z
Ophthalmology | Uveitis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:30 AM
Duration 3mins Stockholm, Sweden
Real-World Treatment Patterns and Visual Outcomes of Faricimab▼ Use Among Eyes With nAMD in the UK: 1-Year Results From the FARWIDE-nAMD Study
Pearce I, Talks J, de Salvo G, Patel P, de Silva S, Gale R, McKibbin M, Varma D, Chi G, James N, Rothwell A, Shah N, Downey A, Dodds M, Dayal P
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
08:35 AM
Duration 3mins Stockholm, Sweden
12-Month Real-World Clinical Outcomes With Faricimab▼ in Patients With Neovascular Age-Related Macular Degeneration: The FARETINA-AMD Study​
Ali F, Tabano D, Ko S, Borkar D, Leng T, Shaia J, Myers R, Singh R
Ophthalmology | Neovascular Age Related Macular Degeneration

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:55 AM
Duration 4mins Stockholm, Sweden
Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Dinah C, Dodds M, Arrisi P, Paris L, Lake A, Nielsen P, Holdsworth J, Saffar I, Chi G
Ophthalmology | Retinal Vein Occlusion

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.